Close Menu

NEW YORK – DiaSorin Molecular said on Wednesday that it has received additional funding from the US Health and Human Services Biomedical Advanced Research and Development Authority to validate its Simplexa COVID-19 Direct kit and Simplexa COVID-19 & Flu A/B Direct kit.

The funding will also be used to submit the kits to the US Food and Drug Administration for 510(k) clearance. Both tests are for use with DiaSorin's Liaison MDX platform.

To read the full story....

...and receive Daily News bulletins.

Already have a 360Dx or GenomeWeb account?
Login Now.

Don't have a 360Dx or GenomeWeb account?
Register for Free.